Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Metrics: PDF 1711 views | HTML 2063 views | ?
Changjun Wang1,*, Bo Pan1,*, Hanjiang Zhu2, Yidong Zhou1, Feng Mao1, Yan Lin1, Qianqian Xu1, Qiang Sun1
1Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China
2Department of Dermatology, University of California, San Francisco, CA, USA
*These authors have contributed equally to this work
Qiang Sun, email: email@example.com
Keywords: androgen receptor, breast cancer, triple negative breast cancer, prognostic value, meta-analysis
Received: April 12, 2016 Accepted: June 03, 2016 Published: June 21, 2016
Background: Androgen receptor (AR) is a promising therapeutic target for breast cancer. However, its prognostic value remains controversial in triple negative breast cancer (TNBC). Here we present a meta-analysis to investigate the correlation between AR expression and TNBC prognosis.
Results: Thirteen relevant studies with 2826 TNBC patients were included. AR positive rate was 24.4%. AR+ patients tended to have lower tumor grade (p< 0.001), but more lymph node metastases (p < 0.01). AR positivity was associated with prolonged disease free survival (HR 0.809, 95% CI = 0.659-0.995, p < 0.05), but had no significant impact on overall survival (HR 1.270, 95% CI=0.904-1.782, p = 0.168). No difference in survival existed between subgroups using different AR or estrogen receptor cutoff values.
Materials and methods: Literature search was performed in Pubmed, Embase and Cochrane Central Register of Controlled Trials databases to identify relevant articles on AR and TNBC prognosis. Fixed- and random-effect meta-analyses were conducted based on the heterogeneity of included studies. Heterogeneity and impacts of covariates were further evaluated by subgroup analyses and meta-regression.
Conclusion: AR positivity is associated with lower risk of disease recurrence in TNBC. Further clinical studies are warranted to clarify its prognostic role on TNBC recurrence and survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.